Figure 3. Enhanced drug delivery to solid tumors using nanoparticles.
(A) Passive targeted delivery. After intravenous injection, nanoparticles accumulate in tumors through leaky and permeable tumor vasculature and impaired lymphatic system (e.g., enhanced permeability and retention effect). (B) Active targeted delivery. Ligand-coated nanoparticles bind to a cancer cell receptor resulting in cell-specific recognition and improved drug delivery to solid tumors.